Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

letter

. 2023 Jul 18;9:73. doi: 10.1038/s41421-023-00554-y

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2023

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 1 — a Schematic map of three Cas12f1 orthologs (AsCas12f1, SpCas12f1 and Un1Cas12f1). b In vitro editing efficiency of three Cas12f1 orthologs for target sites of mouse Trp53 gene in N2a cells. c In vitro editing efficiency for mouse Hpd and Tyr genes with Un1Cas12f1 in N2a cells. d Workflow of embryonic injection of Un1Cas12f1 mRNA and gRNA to generate gene-edited mice. e Gene editing efficiency in mice after embryonic injection of Un1Cas12f1 mRNA and gRNA. f Schematic map of AAV-CjCas9 and AAV-Un1Cas12f1. g Procedure of gene therapy with AAV-CjCas9 and AAV-Un1Cas12f1 in a mouse model of tyrosinaemia. h Deep-sequencing results of gene editing outcomes for liver DNA after Cas12f1 treatment. i Survival curve for tyrosinaemia mice treated with or without AAV-CjCas9 and AAV-Un1Cas12f1. j Mouse weight analysis after treatment with or without AAV-CjCas9 and AAV-Un1Cas12f1. k HPD staining results of liver from tyrosinaemia mice treated with or without AAV-CjCas9 and AAV-Un1Cas12f1. All mice were injected with AAV at the age of 8 weeks. Data are represented as means ± SEM. Scale bars, 200 μm.